Pain Management News

The FDA has approved an abbreviated new drug application for naloxone hydrochloride nasal spray, paving the way for the opioid overdose treatment to be available without a prescription.

BOSTON — There is some evidence that cannabinoids may help with neuropathic pain, chemotherapy-induced nausea/vomiting and MS-associated spasticity, “but it’s not exactly a slam dunk,” a speaker said.

Opioid use was associated with an increased risk for serious falls among all age groups, especially during the first 28 days after initiation, according to a study published in JAMA Internal Medicine.

Silo Pharma will advance a portfolio of four drugs in its 2024 clinical pipeline, targeting conditions related to mental health, chronic pain and neurology.

The FDA has granted breakthrough therapy designation to PF614-MPAR, a “next-generation opioid” designed to limit oral overdose potential, according to a press release from its manufacturer.

Caregivers for those with Lennox Gastaut and Dravet syndrome reported that cannabidiol treatment led to improved nonseizure outcomes and reduced seizure burden, according to a study from Epilepsy Research.

The FDA has approved AvertD, the first DNA test to identify an elevated risk for developing opioid use disorder, according to a press release.

The FDA has issued a warning against the purchase or use of products that contain tianeptine, which has been illegally sold with claims to improve brain function and treat anxiety, depression, pain, opioid use disorder and other conditions.

Long-term treatment with psychedelics holds the potential to transform the health care industry through millions in savings, according to an expert at a congressional briefing hosted by Johns Hopkins University.

Researchers identified multiple predictors of opioid overdose after an opioid prescription for chronic pain in a new study published in CMAJ.